This information is generalized and not intended as specific medical advice. Consult your healthcare professional before taking or discontinuing any drug or commencing any course of treatment.
Severe. These medicines may interact and cause very harmful effects and are usually not taken together. Contact your healthcare professional (e.g. doctor or pharmacist) for more information.
How the interaction occurs:
Your medicine may decrease the amount of hepatitis C medicine your body absorbs.
What might happen:
The amount of hepatitis C medicine in your blood may decrease and it may not work as well.
What you should do about this interaction:
Let your healthcare professionals (e.g. doctor or pharmacist) know right away that you are taking these medicines together or if you have recently taken carbamazepine, oxcarbazepine, phenobarbital, phenytoin, rifabutin, rifampin, rifapentine, St. John's wort, or tipranavir.Your healthcare professionals may already be aware of this interaction and may be monitoring you for it. Do not start, stop, or change the dosage of any medicine before checking with them first.
1.Harvoni (ledipasvir and sofosbuvir) prescribing information. Gilead Sciences February, 2016.
2.Sovaldi (sofosbuvir) US prescribing information. Gilead Sciences, Inc. August, 2015.
3.Epclusa (sofosbuvir and velpatasvir) US prescribing information. Gilead Sciences, Inc. August, 2017.
4.Vosevi (sofosbuvir/velpatasvir/voxilaprevir) US prescribing information. Gilead Sciences, Inc. July, 2017.
5.This information is based on or an extract from the UW Metabolism and Transport Drug Interaction Database (DIDB) Platform, Copyright University of Washington 1999-2014..
6.US Food and Drug Administration (FDA). Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers. Available at: http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/D rugInteractionsLabeling/ucm093664.htm. Updated 08/05/2011.
7.Mavyret (glecaprevir and pibrentasvir) US prescribing information. AbbVie Inc. Aug 2017.